Arcataur Capital Management LLC Purchases 267 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Arcataur Capital Management LLC increased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 34.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,053 shares of the biopharmaceutical company’s stock after buying an additional 267 shares during the period. Arcataur Capital Management LLC’s holdings in Regeneron Pharmaceuticals were worth $750,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of REGN. Rakuten Securities Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 380.0% in the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 19 shares during the last quarter. FSA Wealth Management LLC acquired a new position in shares of Regeneron Pharmaceuticals during the third quarter valued at about $26,000. Fairfield Financial Advisors LTD bought a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter worth about $37,000. Private Wealth Management Group LLC grew its stake in shares of Regeneron Pharmaceuticals by 260.0% in the 4th quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company’s stock valued at $38,000 after buying an additional 39 shares during the period. Finally, Truvestments Capital LLC bought a new stake in Regeneron Pharmaceuticals in the 3rd quarter valued at about $39,000. Institutional investors own 83.31% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have issued reports on REGN shares. UBS Group lowered Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their price target for the stock from $1,130.00 to $738.00 in a report on Thursday, January 16th. Leerink Partners raised shares of Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and lifted their price target for the company from $762.00 to $834.00 in a research report on Wednesday. Wells Fargo & Company lowered their price objective on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating on the stock in a report on Friday, January 10th. Wolfe Research began coverage on shares of Regeneron Pharmaceuticals in a report on Friday, November 15th. They set an “outperform” rating and a $1,150.00 price objective for the company. Finally, Sanford C. Bernstein decreased their target price on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating for the company in a research report on Tuesday, January 7th. One research analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $973.13.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock opened at $710.00 on Friday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 4.73. The firm has a market cap of $78.02 billion, a price-to-earnings ratio of 18.55, a P/E/G ratio of 2.38 and a beta of 0.08. Regeneron Pharmaceuticals, Inc. has a 52 week low of $642.00 and a 52 week high of $1,211.20. The firm’s 50-day simple moving average is $716.62 and its two-hundred day simple moving average is $913.59.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company had revenue of $3.79 billion for the quarter, compared to analysts’ expectations of $3.76 billion. During the same quarter in the previous year, the firm posted $11.86 EPS. Regeneron Pharmaceuticals’s revenue was up 10.3% on a year-over-year basis. As a group, equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 36.67 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th will be paid a dividend of $0.88 per share. The ex-dividend date is Thursday, February 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.50%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.